Buloxibutid

Phase 2Small molecule

Buloxibutid is one of 4 small molecule programs targeting Idiopathic Pulmonary Fibrosis (IPF). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Idiopathic Pulmonary Fibrosis (IPF)Active, not recruiting

Idiopathic Pulmonary Fibrosis (IPF)Phase 2

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Idiopathic Pulmonary Fibrosis (IPF)

#DrugCompanyPhaseTrials

Deupirfenidone

PPureTech

Phase 3

1 2

AK3280

SShanghai Ark Biopharmaceutical Co., Ltd.

Phase 3

1 3

Buloxibutid

VVicore Pharma AB

Phase 2

1 4

LTI-03

RRein Therapeutics

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Active, not recruiting

Idiopathic Pulmonary Fibrosis (IPF)

NCT06588686

Clinical

Trials by Indication[1]

Idiopathic Pulmonary Fibrosis (IPF)1 trial

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Trial Evaluating the Efficacy and Safety of 2 Doses of Buloxibutid Over 52 Weeks in People With Idiopathic Pulmonary Fibrosis.

Active, not recruiting·VVicore Pharma AB·Phase 2·NCT06588686·378 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Buloxibutid. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Buloxibutid compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Buloxibutid. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Vicore Pharma AB company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: VVicore Pharma AB

Buloxibutid

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Idiopathic Pulmonary Fibrosis (IPF)1 trial

References

Drug Info

Quick Facts

Related News